Creighton University School of Medicine

Merck’s KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy Significantly Improved Progression-Free Survival (PFS) Versus Concurrent Chemoradiotherapy Alone in Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, October 20, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Bevacizumab, Neoplasm, FDA, Arm, PD-L1, Standard of care, Cervical cancer, Gynaecology, Hypothyroidism, Catholic higher education, Aes, NYSE, ESMO, Progression-free survival, Food, Trae tha Truth, Cisplatin, Congress, Chemoradiotherapy, MRK, PFS, European Society for Medical Oncology, Obstetrics, GOG, Brachytherapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, HIV disease progression rates, Creighton University School of Medicine, CPS, ClinicalTrials.gov, Merck & Co., Risk, EBRT, Immunotherapy, University, European Network for Health Technology Assessment, Woman, Safety, European Society of Gynaecological Oncology, Cancer, Patient, OS, Death, Pharmaceutical industry, Merck

Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.

Key Points: 
  • Results from the trial showed that KEYTRUDA in combination with concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone for these patients.
  • ET during a late-breaking abstract proffered paper session at the European Society for Medical Oncology (ESMO) Congress 2023 (abstract #LBA38).
  • After a median follow-up of 17.9 months (range, 0.9-31.0), the KEYTRUDA regimen reduced the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.55-0.89]; p=0.0020) versus concurrent chemoradiotherapy alone in these patients.
  • The 24-month PFS rate was 67.8% for patients who received the KEYTRUDA regimen compared to 57.3% for those who received concurrent chemoradiotherapy alone.

William R. Wise, MD, is recognized by Continental Who's Who

Retrieved on: 
Thursday, December 8, 2022
Travel, Hospital, American Medical Association, Indian Medical Association, Person, Suite, American College, MD, BPH, Continental, Incontinence, Sunrise Hospital & Medical Center, Patient, Pebble, Exocrine gland, Creighton University School of Medicine, Urethra, Prostate, Family, Pain, ABU, American Board of Commissioners for Foreign Missions, Pelvic organ prolapse, Multimedia, Fellowship of the Royal Colleges of Surgeons, Kidney, Erectile dysfunction, University, Prostate steam treatment, WISE, Prostate cancer, Candidiasis, Hotel, Medicine, Cathedral Rock, Urology

LAS VEGAS, Dec. 8, 2022 /PRNewswire/ -- William R. Wise, MD, is being recognized by Continental Who's Who as a Trusted Health Care Professional for his exemplary medical contributions and his professional excellence at Las Vegas Urology.

Key Points: 
  • LAS VEGAS, Dec. 8, 2022 /PRNewswire/ -- William R. Wise, MD, is being recognized by Continental Who's Who as a Trusted Health Care Professional for his exemplary medical contributions and his professional excellence at Las Vegas Urology.
  • He then completed an internship, surgical residency, and urology residency at the University of Utah Affiliated Hospitals in Salt Lake City.
  • Wise is experienced in treating common and complex urologic issues for people of all genders.
  • Wise was recognized by Pro News Report in 2021 and was the past President of the Las Vegas Urologic Society.

William R. Wise, MD, is recognized by Continental Who's Who

Retrieved on: 
Thursday, August 18, 2022
Pelvic organ prolapse, Sunrise Hospital & Medical Center, Multimedia, Prostate cancer, Exocrine gland, BPH, Travel, Indian Medical Association, Prostate steam treatment, American Medical Association, Urethra, American Board of Commissioners for Foreign Missions, Suite, Incontinence, Erectile dysfunction, Pain, Continental, American College, Patient, Prostate, Family, Fellowship of the Royal Colleges of Surgeons, Kidney, Creighton University School of Medicine, Candidiasis, Pebble, University, Hospital, ABU, MD, Medicine, Person, Casino, Urology, Cathedral Rock

LAS VEGAS, Aug. 18, 2022 /PRNewswire/ -- William R. Wise, MD, is being recognized by Continental Who's Who as a Trusted Physician for his exemplary medical contributions and in acknowledgment of his outstanding work at Las Vegas Urology.

Key Points: 
  • LAS VEGAS, Aug. 18, 2022 /PRNewswire/ -- William R. Wise, MD, is being recognized by Continental Who's Who as a Trusted Physician for his exemplary medical contributions and in acknowledgment of his outstanding work at Las Vegas Urology.
  • William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.
  • He is dedicated to his patients and is proud to treat them with some of the finest, state-of-the-art equipment available.
  • Wise is experienced in treating common and complex urologic issues for people of all genders.

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status

Retrieved on: 
Monday, June 6, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Woman, University of Arizona College of Medicine – Tucson, EDT, Rucaparib, Lead, Society, Platinum, Journal, Doctor of Philosophy, HIV disease progression rates, Progression-free survival, American Journal of Clinical Oncology, ITT, Peritonitis, FACOG, ASCO, University of Arizona College of Pharmacy, Annual general meeting, Maintenance, Ovarian cancer, University, American Society of Clinical Oncology, HRD, Patient, ATHENA, Risk, Nivolumab, NASDAQ, Creighton University School of Medicine, PFS, Kaplan–Meier estimator, Neoplasm, FACS, BRCA, Mutation, Pharmaceutical industry, MD

The data demonstrate that Rubraca as first-line maintenance treatment significantly improved investigator-assessed progression-free survival (PFS) compared with placebo in women with advanced ovarian cancer irrespective of biomarker status.

Key Points: 
  • The data demonstrate that Rubraca as first-line maintenance treatment significantly improved investigator-assessed progression-free survival (PFS) compared with placebo in women with advanced ovarian cancer irrespective of biomarker status.
  • Currently, the optimal first-line maintenance strategy for treating newly diagnosed advanced ovarian cancer remains unclear, demonstrating the need for treatment advances in this setting.
  • In the exploratory subgroups studied, rucaparib demonstrated treatment benefit versus placebo regardless of BRCA mutation and HRD status.
  • In 2020, GLOBOCAN estimated 314,000 women received a new diagnosis of ovarian cancer and approximately 207,200 women died from ovarian cancer.

William R. Wise, MD is recognized by Continental Who's Who

Retrieved on: 
Thursday, April 21, 2022
Pinnacle, Candidiasis, Patient, ABU, Family, American Board of Commissioners for Foreign Missions, Travel, Pain, Medicine, Urethra, Pebble, Indian Medical Association, Erectile dysfunction, MD, Fellowship of the Royal Colleges of Surgeons, Continental, Creighton University School of Medicine, Hospital, Suite, BPH, Person, Pelvic organ prolapse, Sunrise Hospital & Medical Center, American College, Prostate cancer, Kidney, University, Exocrine gland, Prostate, American Medical Association, Incontinence, Casino, Medical device, Cathedral Rock, Urology

LAS VEGAS, April 21, 2022 /PRNewswire/ --William R. Wise, MD, is being recognized by Continental Who's Who as a Pinnacle Doctor for his medical contributions and in acknowledgment of his professional excellence at Las Vegas Urology.

Key Points: 
  • LAS VEGAS, April 21, 2022 /PRNewswire/ --William R. Wise, MD, is being recognized by Continental Who's Who as a Pinnacle Doctor for his medical contributions and in acknowledgment of his professional excellence at Las Vegas Urology.
  • William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.
  • Wise is experienced in treating common and complex urologic issues for people of all genders.
  • Minimally invasive options are offered at Las Vegas Urology in order to provide same-day procedures and minimize pain and discomfort.

Satellite Healthcare Names Its First Chief Medical Officer – Innovation, Illuminating Its Purpose to Be a Catalyst for the Transformation of Kidney Care

Retrieved on: 
Wednesday, April 13, 2022
Health, Hospitals, Practice Management, Other Health, Managed Care, General Health, Small Satellite Research Laboratory, Kidney, Chronic kidney disease, California Polytechnic State University, Nephrology, Research, Creighton University School of Medicine, MD, CA, St. Rose Dominican Hospital – San Martín Campus, Summit Medical Group, Patient, Dialysis, Kidney disease, Innovation, CMO, Satellite, Physician, University, Knowledge, Renal replacement therapy, Internal medicine, Medical director, Pharmaceutical industry, Hospital, Medicine, Biochemistry

He also serves as Medical Director of Satellite Healthcares Watsonville (CA) Dialysis Center, and Division Chief - Nephrology at Dominican Hospital in Santa Cruz, CA.

Key Points: 
  • He also serves as Medical Director of Satellite Healthcares Watsonville (CA) Dialysis Center, and Division Chief - Nephrology at Dominican Hospital in Santa Cruz, CA.
  • He previously served as Chief Resident and Assistant Clinical Professor in Internal Medicine at the University of California-Davis Medical Center.
  • As Chief Medical Officer Innovation, he will report to Satellite Healthcare CEO Jeff Goffman.
  • Through its affiliated services, Satellite WellBound, Satellite Dialysis, and Satellite Research, Satellite Healthcare provides unparalleled kidney care services addressing patient wellness education, chronic kidney care management, and personalized clinical services.

SERA PROGNOSTICS ANNOUNCES THE APPOINTMENT OF DR. JANE F. BARLOW TO THE SERA PROGNOSTICS BOARD

Retrieved on: 
Tuesday, April 12, 2022
Environmental medicine, Private Securities Litigation Reform Act, Risk, Therapy, Premature, Medco Health Solutions, Creighton University School of Medicine, SEC, University, CEO, Goal, American College, Mother, Intellectual disability, Sale, Seizure, Occupational medicine, CVS Health, Cerebral palsy, Pregnancy, Health, Johns Hopkins University, Job, SALT, View, LLC, Indian Medical Association, Pharmacy, Executive, NASDAQ, Death, Multimedia, American College of Preventive Medicine, Preterm birth, FDA, CPT, Protein, Patient, Adoption, Company, American Medical Association, Sumathi Best Television Current Reporting Award, American College of Occupational and Environmental Medicine, Hearing loss, Woman, Associate, Learning, COVID-19, Physician, Blood, Health insurance, Pharmaceutical industry, Birth control

SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Dr. Jane F. Barlow has joined the Sera Board of Directors.

Key Points: 
  • "We are very excited to have Dr. Jane Barlow join Sera's talented board," said Gregory C. Critchfield, CEO and Chairman of Sera Prognostics.
  • "Jane possesses deep expertise in bringing novel products and services to the market, through operations, strategy development and board experiences.
  • Dr. Barlow also serves on the board of directors of Point Health, a healthcare navigation platform, the advisory board of Refactor Health, and the Biotech Advisory Board of Pictet Asset Management, an asset management firm.
  • Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

Takeshi Seto, MD, is recognized by Continental Who's Who

Retrieved on: 
Friday, February 18, 2022
Asthma, Mathematics, University, Physician, Patient, Allergy, Respiratory system, American Board of Internal Medicine, Medicine, Sleep medicine, American College of Chest Physicians, Mentorship, AdventHealth, American College, Creighton University School of Medicine, American Board of Commissioners for Foreign Missions, Allergic rhinitis, Critical care, Fellowship (medicine), MD, Internal medicine, View, Critical Care Medicine (journal), Creighton University, OSA, Degenerative disease, ABIM, COPD, Sleep, Multimedia, Continental, Bachelor of Science in Paramedicine, Obstructive sleep apnea, Chronic obstructive pulmonary disease, Sleep apnea, Hospital

OTTAWA, Kan., Feb. 17, 2022 /PRNewswire/ --Takeshi Seto, MD, is being recognized by Continental Who's Who as a Trusted Physician for his work in the Medical field and in acknowledgment of his work at AdventHealth Hospital.

Key Points: 
  • OTTAWA, Kan., Feb. 17, 2022 /PRNewswire/ --Takeshi Seto, MD, is being recognized by Continental Who's Who as a Trusted Physician for his work in the Medical field and in acknowledgment of his work at AdventHealth Hospital.
  • Dr. Takeshi Seto, MD, is a respected Pulmonologist who has dedicated over 34 years to the Medical field.
  • In his current work, Dr. Seto provides Critical Care Pulmonology services to inpatients at AdventHealth locations at 1428 South Main St. Ste.
  • Dr. Seto is board-certified in Pulmonary Disease, Critical Care Medicine, Sleep Medicine, and Internal Medicine by the American Board of Internal Medicine (ABIM).

William R. Wise, MD, is being recognized by Continental Who's Who as a Distinguished Doctor for medical contributions in the Medical field and his professional excellence at Las Vegas Urology.

Retrieved on: 
Monday, January 24, 2022
Candidiasis, Patient, American Board of Commissioners for Foreign Missions, Person, ABU, Sunrise Hospital & Medical Center, Prostate, Suite, Prostate cancer, Exocrine gland, Urethra, Travel, Pebble, Indian Medical Association, Pelvic organ prolapse, BPH, Erectile dysfunction, American Medical Association, Creighton University School of Medicine, Pain, Fellowship of the Royal Colleges of Surgeons, Incontinence, MD, Multimedia, American College, Family, Kidney, Hospital, University, Cathedral Rock, Urology, Medicine

LAS VEGAS, Jan. 24, 2022 /PRNewswire/ -- William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.

Key Points: 
  • LAS VEGAS, Jan. 24, 2022 /PRNewswire/ -- William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.
  • Minimally invasive options are offered at Las Vegas Urology in order to provide same-day procedures, and minimize pain and discomfort.
  • Las Vegas Urology is currently offering video e-visits and telehealth options throughout its eight locations in Nevada.
  • Wise is a member of the American Medical Association, Clark County Medical Society, Las Vegas Urologic Society, and American Urological Association Western Section.

William R. Wise, MD, is recognized by Continental Who's Who

Retrieved on: 
Monday, December 27, 2021
Creighton University School of Medicine, Indian Medical Association, ABU, Patient, Pebble, BPH, Travel, Pain, American Board of Commissioners for Foreign Missions, Prostate, Pelvic organ prolapse, University, Continental, Kidney, Sunrise Hospital & Medical Center, Family, Prostate cancer, MD, Candidiasis, Erectile dysfunction, Urethra, Fellowship of the Royal Colleges of Surgeons, Exocrine gland, American Medical Association, Incontinence, American College, Hospital, Medical device, Urology, Medicine, Cathedral Rock

LAS VEGAS, Dec. 27, 2021 /PRNewswire/ -- William R. Wise, MD, is being recognized by Continental Who's Who as a Distinguished Doctor for medical contributions in the Medical field and his professional excellence at Las Vegas Urology.

Key Points: 
  • LAS VEGAS, Dec. 27, 2021 /PRNewswire/ -- William R. Wise, MD, is being recognized by Continental Who's Who as a Distinguished Doctor for medical contributions in the Medical field and his professional excellence at Las Vegas Urology.
  • William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.
  • Wise is experienced in treating both common and complex urologic issues for people of all genders.
  • Minimally invasive options are offered at Las Vegas Urology in order to provide same-day procedures, and minimize pain and discomfort.